SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
This article was originally published in The Gray Sheet
Executive Summary
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel